Findings

What do systematic reviews say?

1 questions · 2 findings · 1 reviews

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 2 · 100%High 0 · 0%

Failure to maintain clinical response · people with moderate to severe Crohn's disease in remission

Ustekinumab probably leads to lower failure to maintain clinical response compared with placebo (moderate certainty).

2 findings from 1 review

Anti‐IL‐12/23p40 antibodies for maintenance of remission in Crohn's disease 2019 · Cochrane Headline outcomes only
RR 0.53 [0.36, 0.79]
1 study · 145 participants
Moderate
Anti‐IL‐12/23p40 antibodies for maintenance of remission in Crohn's disease 2019 · Cochrane Headline outcomes only
RR 0.74 [0.6, 0.91]
1 study · 388 participants
Moderate